Prolynx
Latest round
- Series A
Last raised
- Dec 2025
Total raised
- $70M
Investors
- 3
About Prolynx
Founded in 2009 and headquartered in San Francisco, US, Prolynx develops therapeutic candidates aimed at addressing obesity and metabolic disorders.Prolynx is focused on developing a portfolio of ultra-long-acting therapeutic candidates aimed at addressing obesity and related metabolic diseases. Their core products leverage proprietary half-life extension technology, allowing for once-monthly and once-quarterly dosing regimens. This technology enhances treatment consistency, improves tolerability, and optimizes pharmacokinetics, ultimately aiming to provide patients with a more manageable approach to long-term weight management and metabolic health.Prolynx's revenue model is structured around strategic partnerships and potential collaborations with healthcare providers and pharmaceutical distributors. The company is expected to generate revenue through the sale of its ultra-long-acting medicines, marketed directly to healthcare institutions and clinics specializing in obesity and metabolic disease treatment. Transactions will involve agreements with healthcare providers to supply these products, potentially incorporating subscription models for ongoing treatment regimens. Additionally, Prolynx aims to expand its presence in North America and Europe, targeting healthcare providers that specialize in these conditions.
Who invested in Prolynx
3 investors across 1 round
See all investors in Prolynx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 11, 2025
Amount
$70M
Investors
Questions about Prolynx
Who invested in Prolynx?
Prolynx has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Prolynx raised?
Prolynx has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Prolynx last raise money?
Prolynx's most recent round on record is a Series A, in Dec 2025.
What does Prolynx do?
Founded in 2009 and headquartered in San Francisco, US, Prolynx develops therapeutic candidates aimed at addressing obesity and metabolic disorders.
Where is Prolynx headquartered?
Prolynx is headquartered in San Francisco, US.
Which VCs invest in companies like Prolynx?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Prolynx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Prolynx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.